Mosquirix (RTS,S): A novel vaccine for the prevention of Plasmodium falciparum malaria;Mosquirix (RTS,S): Un nouveau vaccine pour la prévention de la malaria à Plasmodium falciparum

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 384-393

  Wilby, Kyle J ^a   Lau, Tim T Y ^b   Gilchrist, Samuel E ^a   Ensom, Mary H H ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c Distinguished University Scholar   (Canada)

Author keywords

Malaria; Pediatrics; Plasmodium falciparum; RTS,S; Vaccine

Indexed keywords

AS 01E; AS 02A; AS 02D; CIRCUMSPOROZOITE PROTEIN; CIRCUMSPOROZOITE PROTEIN ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MENINGOCOCCUS VACCINE; MOSQUIRIX; ORAL POLIOMYELITIS VACCINE; PARASITE ANTIBODY; PNEUMOCOCCUS VACCINE; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANEMIA; ANTIBODY TITER; ARTICLE; BED NET; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE SEVERITY; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE CONVULSION; FOLLOW UP; GASTROENTERITIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; LIVER CELL; MALARIA; MALARIA FALCIPARUM; MALNUTRITION; MENINGITIS; NONHUMAN; PARASITEMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINORRHEA; SIDE EFFECT; SYSTEMATIC REVIEW; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

EID: 84858012686     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q634     Document Type: Article

References (24)

1. World Health Organization. Factsheet on malaria. www.who.int/mediacentre/factsheets/fs094/en/ (accessed 19 Sept 2011).
2. Baird KJ. Effectiveness of antimalarial drugs. N Engl J Med 2005;352: 1565-77.
3. Casares S, Brumeanu T, Richie TL. The RTS,S malaria vaccine. Vaccine 2010;28:4880-94.
4. Sowunmi A. Hepatomegaly in acute falciparum malaria in children. T Roy Soc Trop Med H 1996;90:540-2.
5. Jones TR, Hoffman SL. Malaria vaccine development. Clin Microbiol Rev 1994;7:303-10.
6. GSK Biologicals, malaria vaccine initiative. Fact sheet: RTS,S Malaria vaccine candidate. www.worldmalariaday.org/download/partners/Updated_RTSS_FactSheet_21_April_2010.pdf (accessed 19 Sept 2011).
7. Dame JB, Williams JL, McCutchan TF, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984;225:593-9.
8. Ansong D, Asante KP, Vekemans J, et al. T cell responses to the RTS,S/AS01E and RTS,S/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS ONE 2011;6:e18891.
9. Loucq C. The RTS,S/AS malaria vaccine candidate: results of phase 2 studies; design and status of the phase 3 trial. www.who.int/immunization/sage/20091028_MVI_SAGE_LOUCQ_FinalDraft.pdf (accessed 20 Sept 2011).
10. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 2004;364:1411-20.
11. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521-32.
12. Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008;359:2533-44.
13. Aponte JJ, Aide P, Renom M, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomized controlled phase I/IIb trial. Lancet 2007;370:1543-51.
14. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011;365:1863-75. DOI 10.1056/NEJMoa1102287
15. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized controlled trial. Lancet 2005;366:2012-8.
16. Sacarlal J, Aide P, Aponte JJ, et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009;200:329-36.
17. Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomized controlled trial. Lancet Infect Dis 2011;11:102-9.
18. Aide P, Aponte JJ, Renom M, et al. Safety, immunogenicity and duration of protection of the RTS,S/AS02D malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS ONE 2010;5:e13838.
19. World Health Organization. Malaria: disease burden in SEA region. www.searo.who.int/en/Section10/Section21/Section340_4018.htm (accessed 7 Nov 2011).
20. Polhemus ME, Remich SA, Ogutu BR, et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 2009;4:e6465.
21. Olotu A. RTS,S Phase III update. www.who.int/vaccine_research/docu-ments/Session3_Olotu_presentation.pdf (accessed 6 Oct 2011).
22. nd ed. http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf (accessed 10 Sept 2011).
23. McGready R, White NJ, Nosten F. Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. BJOG 2011;118:123-35.
24. Levine OS, Bloom DE, Cherian T, et al. The future of immunization policy, implementation, and financing. Lancet 2011;378:439-48.